Unknown

Dataset Information

0

IL-21-Deficient T Follicular Helper Cells Support B Cell Responses Through IL-27 in Patients With Chronic Hepatitis B.


ABSTRACT: Chronic Hepatitis B (CHB) affects over 350 million people worldwide. Current treatment does result in reduced complications; however, a cure (development of antibodies to the S antigen) is not achieved, requiring life-long therapy. Humoral responses contribute to viral elimination by secreting neutralizing antibodies; though, effective induction of humoral immunity require CD4T cell differentiation into T follicular helper (TFH) cells that support B cell response through interleukin-21 (IL-21). In CHB, mechanism of TFH-B interactions is seldom described. During CHB, TFH cells are defective in producing IL-21 in response to hepatitis B surface antigen (HBsAg). However, regardless of low IL-21, TFH cells efficiently support B cell responses by producing interleukin-27 (IL-27), which directs the formation of plasmablasts and plasma cells from memory and naïve B cells by enhancing B lymphocyte-induced maturation protein-1. IL-27 not only improved total antibody production but HBsAg-specific IgG and IgM secretion that are essential for viral clearance. Importantly, IL-27+TFH cells were significantly associated with HBV DNA reduction. Therefore, these findings imply a novel mechanism of TFH mediated B cell help in CHB and suggest that IL-27 effectively compensate the function of IL-21 by supporting TFH-B cell function, required for protective antibody response and may contribute to viral clearance by providing potential target for achieving a functional cure.

SUBMITTER: Khanam A 

PROVIDER: S-EPMC7876309 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature

altmetric image

Publications

IL-21-Deficient T Follicular Helper Cells Support B Cell Responses Through IL-27 in Patients With Chronic Hepatitis B.

Khanam Arshi A   Ayithan Natarajan N   Tang Lydia L   Poonia Bhawna B   Kottilil Shyam S  

Frontiers in immunology 20210128


Chronic Hepatitis B (CHB) affects over 350 million people worldwide. Current treatment does result in reduced complications; however, a cure (development of antibodies to the S antigen) is not achieved, requiring life-long therapy. Humoral responses contribute to viral elimination by secreting neutralizing antibodies; though, effective induction of humoral immunity require CD4T cell differentiation into T follicular helper (T<sub>FH</sub>) cells that support B cell response through interleukin-2  ...[more]

Similar Datasets

| S-EPMC8044369 | biostudies-literature
| S-EPMC6307283 | biostudies-literature
| S-EPMC7746526 | biostudies-literature
| S-EPMC5671557 | biostudies-literature
| S-EPMC3702561 | biostudies-literature
| S-EPMC6791812 | biostudies-literature
| S-EPMC10454845 | biostudies-literature
| S-EPMC7144868 | biostudies-literature
| S-EPMC8345153 | biostudies-literature